Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024]
Ann Oncol. 2021 Oct;32(10):1307.
doi: 10.1016/j.annonc.2021.07.011.
Epub 2021 Aug 16.
1 David Geffen School of Medicine at UCLA, Los Angeles, USA. Electronic address: dslamon@mednet.ucla.edu.
2 Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium.
3 British Columbia Cancer Agency, Vancouver, Canada.
4 CHU Liege and Liège University, Liège, Belgium.
5 Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy.
6 Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
7 Masaryk Memorial Cancer Institute, Brno, Czech Republic.
8 Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy.
9 Instituto de Investigación Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid, Spain.
10 Practice for Hematology and Internal Oncology, Velbert, Germany.
11 Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, The Netherlands.
14 Novartis Pharmaceuticals Corporation, East Hanover, USA.
15 Novartis Pharma AG, Basel, Switzerland.
16 Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen, Erlangen, Germany.